Wolfe Research downgrades Scholar Rock Holding to Peer Perform from Outperform
Wolfe Research downgraded Scholar Rock Holding from Outperform to Peer Perform. The change in rating may impact investor sentiment and stock performance.
Scholar Rock Holding Corp
Scholar Rock is a biopharmaceutical company developing therapies for children and adults with spinal muscular atrophy and other rare, severe neuromuscular diseases. It uses a proprietary platform to discover monoclonal antibodies that selectively target inactive precursor forms of growth factors. Its lead investigational product, apitegromab, is an anti-myostatin antibody in development for SMA and facioscapulohumeral muscular dystrophy, with both intravenous and subcutaneous formulations. Its clinical-stage pipeline also includes SRK-439, a subcutaneous anti-myostatin antibody for rare neuromuscular diseases. Scholar Rock’s early-stage programs include candidates for solid tumors, fibrotic diseases and iron-restricted anemias. The company is seeking partners for these additional programs. It is also developing a commercial organization to support apitegromab, with a U.S. customer-facing team and a European build-out starting with Germany. Scholar Rock is headquartered in Cambridge, Massachusetts.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Wolfe Research downgraded Scholar Rock Holding from Outperform to Peer Perform. The change in rating may impact investor sentiment and stock performance.
Scholar Rock (SRRK) reported Q3 2026 earnings, highlighting FDA approval of ISEMBYLD for SMA, a $205M deal for a priority review voucher, and progress in Japan and Phase II FORGE study. ISEMBYLD showed a 2.2-point motor function improvement in trials, with strong early launch demand. The company reported $0.6M in ISEMBYLD revenue and $413.6M in cash, with no immediate need for equity offering.
Scholar Rock (SRRK) reported Q3 earnings, noting no demand impact from a bone fracture warning. The company resubmitted its European marketing application for apitegromab, expecting a decision in early 2027. It anticipates a 2027 launch in Japan and Germany. Operating expenses were $106.6M, with $413.6M in cash. SRRK sold a priority review voucher for $205M and has access to an additional $150M under its debt facility.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning SRRK (Scholar Rock Holding Corp). Coverage has been balanced: 1 bullish, 0 neutral, and 1 bearish.
Recent SRRK coverage spans earnings, financial news and mergers & acquisitions.
In the last 30 days, SRRK insiders filed 6 SEC Form 4 transactions — 6 purchases ($12.0M) and no sales. The most active reporter was AKKARAJU SRINIVAS with 6 filings.
The downgrade signals reduced confidence in the company's near‑term prospects.
Balance‑sheet strengthening and early launch metrics suggest positive sentiment.
Cash infusion from voucher sale and solid balance sheet may support upside, but lack of new guidance limits impact.
Positive catalyst from FDA approval and analyst upgrade.
Earnings beat on EPS but revenue miss may cause mixed investor reaction.
AlphAI scores every news story that mentions SRRK with an AI model for sentiment and relevance, and aggregates insider trades from Scholar Rock Holding Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Wolfe Research downgraded Scholar Rock Holding from Outperform to Peer Perform. The change in rating may impact investor sentiment and stock performance.
Scholar Rock (SRRK) reported Q3 2026 earnings, highlighting FDA approval of ISEMBYLD for SMA, a $205M deal for a priority review voucher, and progress in Japan and Phase II FORGE study. ISEMBYLD showed a 2.2-point motor function improvement in trials, with strong early launch demand. The company reported $0.6M in ISEMBYLD revenue and $413.6M in cash, with no immediate need for equity offering.
Scholar Rock (SRRK) reported Q3 earnings, noting no demand impact from a bone fracture warning. The company resubmitted its European marketing application for apitegromab, expecting a decision in early 2027. It anticipates a 2027 launch in Japan and Germany. Operating expenses were $106.6M, with $413.6M in cash. SRRK sold a priority review voucher for $205M and has access to an additional $150M under its debt facility.
Raymond James maintained a Strong Buy rating and $72.00 price target for Scholar Rock (NASDAQ: SRRK) after its Q3 2026 results. The stock is up 17% this week and 76% over the past year. Scholar Rock reported its first product revenues for ISEMBYLD, which received FDA approval in September 2026. The company's EPS beat estimates but revenue missed expectations, falling 60.14% short of forecasts.
Scholar Rock (SRRK) reported Q3 EPS of -$0.81, beating estimates by $0.03, but revenue of $570K missed expectations of $1.43M. The stock is down 1.85% over 3 months but up 67.42% year-over-year. InvestingPro rates its financial health as 'fair performance'.
Scholar Rock (SRRK) agreed to sell its FDA Priority Review Voucher to BioNTech for $205M in cash. The payment is due at closing, pending regulatory approval. The voucher was awarded after FDA approval of ISEMBYLD. The transaction aims to monetize the voucher.
Scholar Rock Holding Corp (SRRK) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Scholar Rock Reports Third Quarter 2026 Financial Results and Recent Business Highlights • U.S. launch of ISEMBYLD™ (apitegromab-mstn), the first and only muscle-targeted therapy for children and adults living with spinal muscular atrophy (SMA), underway following Se
Scholar Rock (SRRK) director acquired $12M in shares at $41.31-$41.82, indirectly via investment entities. Stride (LRN) director bought $12.18M in shares at $78.44-$79.84. Data I/O (DAIO) 10% owner bought $999,996 in stock and $3M in convertible debentures. Nuveen (NUV) trustee purchased $300,394 in shares. Talos (TALO) 10% owner sold $45.82M in shares at $18.20-$18.51. Snowflake (SNOW) director sold $16.95M in shares at $339.08. Goldman Sachs (GS) CEO sold $10.93M in shares at $910.46-$912.11.
AKKARAJU SRINIVAS purchased 289,470 indirectly-held shares of Scholar Rock Holding Corp (SRRK) at an average of $41.45 ($41.31–$41.82, $12.00M total) across 6 trades over 2026-10-23 to 2026-10-26.
Truist Securities reiterated a Buy rating and $77 price target for Scholar Rock (SRRK), citing potential uptake of its Isembyld treatment for spinal muscular atrophy. Analysts expect 50-60% of patients to use the drug within five years, with key opinion leaders validating trial results and noting functional improvements. The stock trades at $41.14, with a Strong Buy consensus and price targets ranging from $58 to $84.